Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 5/20 | 0.34 |
| ▸ | MMP9 | P14780 | 5/20 | 0.34 |
| ▸ | MMP8 | P22894 | 5/20 | 0.34 |
| ▸ | MMP14 | P50281 | 5/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239160 | 0.84 | PGR (0.37) | ST14LOXL2LNPEPLOXALDH1A1 | |
| SCHEMBL20239133 | 0.80 | KDR (0.41) | CA1CA2CA5ACA9P2RX3 | |
| SCHEMBL20239328 | 0.78 | DGAT2 (0.47) | CA1CA2CA9DGAT2LNPEP | |
| SCHEMBL18249838 | 0.78 | LOXL2 (0.62) | LOXL2LOX | |
| SCHEMBL20472857 | 0.76 | PGR (0.52) | CA1CA2CA9ALDH1A1HTT | |
| SCHEMBL1680487 | 0.76 | LOXL2 (0.54) | LOXL2LOXALDH1A1HTT | |
| SCHEMBL4363917 | 0.73 | MAOB (0.54) | CA1CA2CA5ACA9LOXL2 | |
| SCHEMBL20239207 | 0.73 | SMN1; SMN2 (0.48) | ST14CA1CA2CA5ACA9 | |
| SCHEMBL16738665 | 0.72 | DGAT2 (0.44) | ST14CA1CA2CA5ACA9 | |
| SCHEMBL20239260 | 0.69 | DGAT2 (0.46) | ST14CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | ST14 4842/4885CA1 4849/4885CA2 4773/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | ST14 4847/4885CA1 4830/4885CA2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.